Abstract
The aim of this study was to compare a clinic-based enzyme-linked immunosorbent assay (immunocomb-Eliza, Biogal, Israel) and a field-based dot-blot enzyme-linked immunoassay (DBELIA) with the indirect immunofluoresence antibody test (IFAT) used for the field diagnostics of canine monocytic ehrlichiosis (CME). The total test samples was 60; out of them 52 serum samples came from naturally exposed police German shepherd dogs and 8 from adult mongrels infected with viable Ehrlichia canis propagated in a dog macrophage laboratory cell line (DH82). The DBELIA test was positive in 86.7% (56/60) and negative in 13.3% (8/60), while the immunocomb-Eliza was positive in 91.7% (55/60) and negative in 8.3% (5/60). IFAT revealed 90.0% (54/60) of DBELIA samples as positive while 10.0% (6/50) as negative, with an agreement of 83.3% (50/60). IFAT revealed 96.7% (58/60) of immunocomb-Eliza samples as positive and 3.3% (2/60) as negative, with an agreement of 91.7% (55/60). There was an overall agreement of 86.7% (52/60) among the three assays. Five (62.5%) of the 8 disagreement were of low IFAT, titre range < 1:240 attributable to false initial IFAT results from non-specific antibody binding, cross-reactivity or antigenic variations. A positive correlation was observed in the results of the 3 assays with correlation coefficients (r2) of 0.8214 at P < 0.0001 and 0.8984 at P < 0.001 for IFAT-DBELIA and IFAT-immunocomb-Eliza, respectively. No statistically significant differences were observed in their results. The chi-square values were 0.9021, P-0.3142 and 0.04322, P-0.7624 for DBELIA and immunocomb-Eliza, respectively. Sensitivities and specificities were 92.6%, 83% and 96.0%, 87.0% for DBELIA and immunocomb-Eliza, respectively. When based on IFAT titre range of over 1:240. Both assays were sensitive and specific for the field diagnosis of CME but the immunocomb-Eliza is more sensitive and specific than the DBELIA, but the latter saves time, requires no special equipment and personnel and has a preservable shelf-life (>1 year) for its dot-antigen package.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.